Elizabeth Holmes and Billy Evans: Key Facts
Elizabeth Holmes founded Theranos in 2003 and served as CEO until the company was dissolved. Billy Evans was a Theranos board member and early investor. The Theranos scandal led to criminal fraud charges against Holmes in the United States. Holmes was convicted on four counts of defrauding investors in January 2022. Sentencing included prison time, restitution, and forfeiture related to the fraud scheme. Billy Evans remained associated with Theranos during its peak and subsequent collapse.
Theranos claimed its technology could run hundreds of medical tests with a few drops of blood. Regulatory agencies, including the U.S. Food and Drug Administration, found the technology did not work as claimed. The company's board included individuals with business and finance backgrounds. Holmes and former COO Sunny Balwani were charged by federal prosecutors. The case drew attention to startup governance and due diligence in health technology. Billy Evans is referenced in court filings and reporting as a board-level participant.
Theranos Collapse and Legal Outcomes
Theranos was valued at about $9 billion at its peak before the scandal surfaced. The company's laboratory operations were flagged by the Centers for Medicare and Medicaid Services. Regulatory actions included revocation of Theranos's clinical laboratory license. Holmes and Balwani were found guilty on multiple fraud counts. The U.S. Securities and Exchange Commission also brought civil charges against Holmes. Investors and patients were identified as victims of the fraud scheme.
Sentencing documents outlined financial penalties and restitution orders. Holmes was ordered to pay millions in restitution to victims. The case is cited in discussions about startup due diligence and board oversight. Billy Evans's role is described in legal and journalistic accounts of Theranos's governance. The collapse led to changes in health technology regulation and investor scrutiny. Theranos's failure is used as a reference point in fintech and health-tech risk analysis.
Financial and Industry Impact
Theranos's collapse affected investor confidence in health-tech startups. The case highlighted risks of overvaluation without validated technology. Regulatory bodies increased scrutiny of blood-testing and diagnostic companies. Holmes's conviction is referenced in corporate governance and compliance training. The Theranos story is studied in business school cases on ethics and due diligence. Billy Evans's involvement is noted in analyses of board composition and risk management.
Financial records from Theranos showed significant capital raises before the fraud was exposed. Investors included wealthy individuals, funds, and strategic partners. The SEC focused on misleading claims about Theranos's technology and revenue. Court filings detail the flow of funds and investor losses. The case influenced disclosure rules and board liability standards. Billy Evans is mentioned in reports that analyze Theranos's financial and governance failures.
Sources and References
For a detailed timeline of the Theranos case, see the Forbes overview of Theranos. Regulatory and legal details are available on the SEC litigation release and the Department of Justice press release. Additional context on Theranos governance and board roles can be found in the Theranos historical site.